<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866643</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-38505</org_study_id>
    <nct_id>NCT02866643</nct_id>
  </id_info>
  <brief_title>Labor and Delivery Implant Insertion: A Randomized Controlled Trial</brief_title>
  <acronym>LADII</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A barrier to initiating progestin contraceptives in the early postpartum period is the
      concern of interference with breastfeeding, specifically lactogenesis. In this trial, the
      investigators aim to add to safety data on the effects of immediate insertion of the
      contraceptive implant on breastfeeding. The investigators seek to examine the time to
      lactogenesis with immediate post-delivery insertion in delivery room versus insertion of a
      contraceptive implant in the postpartum ward prior to medical discharge. For this study, 82
      consenting women will be randomized to immediate implant insertion (0-2 hours following
      delivery) in the delivery room or insertion of the implant following delivery in postpartum
      room and prior to medical discharge (24-48 hours following delivery).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Lactogenesis Stage II [Questionnaire]</measure>
    <time_frame>Participants will be monitored daily by the research staff, in the first seven days postpartum, or until lactogenesis reported, beginning at 24-hours following delivery, to determine time to lactogenesis stage II.</time_frame>
    <description>Lactogenesis Stage II: The initiation of copious milk secretion as documented by maternal perception.
To obtain measurement of time to lactogenesis, we will document time at which participants perceive initiation of copious milk secretion using a set of specific validated questions and subtract this by the documented time of delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding continuation and exclusivity [Questionnaire]</measure>
    <time_frame>The investigators will administer a questionnaire using Redcap (TM) software at 4-8 weeks, 3, 6, and 12 months following insertion of contraceptive implant.</time_frame>
    <description>The questionnaire will ask questions about breastfeeding continuation, supplementation, duration, and exclusivity. This questionnaire will also include questions about contraceptive continuation, patient satisfaction with implant, pregnancy, and postpartum care visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraceptive continuation [Questionnaire]</measure>
    <time_frame>The investigators will administer a questionnaire using Redcap (TM) software at 4-8 weeks, 3, 6, and 12 months following insertion of contraceptive implant.</time_frame>
    <description>The questionnaire will ask questions about contraceptive continuation with the implant and other forms of contraception. This questionnaire will also include questions about breastfeeding continuation, supplementation, duration, and exclusivity, contraceptive continuation, patient satisfaction with implant, pregnancy, and postpartum care visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with choice of implant as form of postpartum contraception [Questionnaire]</measure>
    <time_frame>The investigators will administer a questionnaire using Redcap (TM) software at 4-8 weeks, 3, 6, and 12 months following insertion of contraceptive implant.</time_frame>
    <description>The questionnaire will ask questions about patient satisfaction with use of the implant. This questionnaire will also include questions about breastfeeding continuation, supplementation, duration, and exclusivity, contraceptive continuation,pregnancy, and postpartum care visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rates [Questionnaire]</measure>
    <time_frame>The investigators will administer a questionnaire using Redcap (TM) software at 4-8 weeks, 3, 6, and 12 months following insertion of contraceptive implant.</time_frame>
    <description>The questionnaire will ask questions about subsequent pregnancy. This questionnaire will also include questions about breastfeeding continuation, supplementation, duration, and exclusivity, contraceptive continuation, patient satisfaction with implant, and postpartum care visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum care visits [Questionnaire]</measure>
    <time_frame>The investigators will administer a questionnaire using Redcap (TM) software at 4-8 weeks, 3, 6, and 12 months following insertion of contraceptive implant.</time_frame>
    <description>The questionnaire will ask questions about postpartum care visits. This questionnaire will also include questions about breastfeeding continuation, supplementation, duration, and exclusivity, contraceptive continuation, patient satisfaction with implant, and pregnancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Postpartum Contraception</condition>
  <condition>Family Planning</condition>
  <arm_group>
    <arm_group_label>Delivery Room Insertion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postpartum Insertion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel-Immediate</intervention_name>
    <description>The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).</description>
    <arm_group_label>Delivery Room Insertion</arm_group_label>
    <other_name>Nexplanon</other_name>
    <other_name>Contraceptive Implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel-Delayed</intervention_name>
    <description>The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.</description>
    <arm_group_label>Postpartum Insertion</arm_group_label>
    <other_name>Nexplanon</other_name>
    <other_name>Contraceptive Implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy pregnant women

          -  Intend to breastfeed

          -  Desire the contraceptive implant as their method of contraception

          -  Agree to be randomized to delivery room vs. postpartum ward insertion

          -  Have delivered a healthy term infant (37 weeks gestation)

        Exclusion Criteria:

          -  Not English or Spanish speaking

          -  Allergy or Contraindication to contraceptive implant.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate A Shaw, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate A Shaw, MD, MS</last_name>
    <phone>650-721-1562</phone>
    <email>familyplanningresearch@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klaira Lerma, MPH</last_name>
    <phone>65072111</phone>
    <email>klerma@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrics--Lucile Packard Children's Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaira M Lerma, MPH</last_name>
      <phone>650-721-1562</phone>
      <email>familyplanningresearch@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kate A Shaw, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finer LB, Zolna MR. Declines in Unintended Pregnancy in the United States, 2008-2011. N Engl J Med. 2016 Mar 3;374(9):843-52. doi: 10.1056/NEJMsa1506575.</citation>
    <PMID>26962904</PMID>
  </reference>
  <reference>
    <citation>Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. Int J Gynaecol Obstet. 2005 Apr;89 Suppl 1:S25-33.</citation>
    <PMID>15820365</PMID>
  </reference>
  <reference>
    <citation>Zhu BP, Rolfs RT, Nangle BE, Horan JM. Effect of the interval between pregnancies on perinatal outcomes. N Engl J Med. 1999 Feb 25;340(8):589-94.</citation>
    <PMID>10029642</PMID>
  </reference>
  <reference>
    <citation>Mayer JP. Unintended childbearing, maternal beliefs, and delay of prenatal care. Birth. 1997 Dec;24(4):247-52.</citation>
    <PMID>9460316</PMID>
  </reference>
  <reference>
    <citation>Heller R, Cameron S, Briggs R, Forson N, Glasier A. Postpartum contraception: a missed opportunity to prevent unintended pregnancy and short inter-pregnancy intervals. J Fam Plann Reprod Health Care. 2016 Apr;42(2):93-8. doi: 10.1136/jfprhc-2014-101165. Epub 2015 Dec 8.</citation>
    <PMID>26645197</PMID>
  </reference>
  <reference>
    <citation>Speroff L, Mishell DR Jr. The postpartum visit: it's time for a change in order to optimally initiate contraception. Contraception. 2008 Aug;78(2):90-8. doi: 10.1016/j.contraception.2008.04.005. Epub 2008 Jun 12.</citation>
    <PMID>18672108</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Postpartum care visits--11 states and New York City, 2004. MMWR Morb Mortal Wkly Rep. 2007 Dec 21;56(50):1312-6.</citation>
    <PMID>18097343</PMID>
  </reference>
  <reference>
    <citation>Gariepy AM, Duffy JY, Xu X. Cost-Effectiveness of Immediate Compared With Delayed Postpartum Etonogestrel Implant Insertion. Obstet Gynecol. 2015 Jul;126(1):47-55. doi: 10.1097/AOG.0000000000000907.</citation>
    <PMID>26241255</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Contraceptive use among postpartum women - 12 states and New York City, 2004-2006. MMWR Morb Mortal Wkly Rep. 2009 Aug 7;58(30):821-6.</citation>
    <PMID>19661855</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):878-83.</citation>
    <PMID>21734635</PMID>
  </reference>
  <reference>
    <citation>Medical Eligibility Criteria for Contraceptive Use. 5th edition. Geneva: World Health Organization; 2015.</citation>
    <PMID>26447268</PMID>
  </reference>
  <reference>
    <citation>Dunn K, Bayer LL, Mody SK. Postpartum contraception: An exploratory study of lactation consultants' knowledge and practices. Contraception. 2016 Jul;94(1):87-92. doi: 10.1016/j.contraception.2016.03.007. Epub 2016 Mar 17.</citation>
    <PMID>26996737</PMID>
  </reference>
  <reference>
    <citation>Duvan Cİ, Gözdemir E, Kaygusuz I, Kamalak Z, Turhan NÖ. Etonogestrel contraceptive implant (Implanon): analysis of patient compliance and adverse effects in the breastfeeding period. J Turk Ger Gynecol Assoc. 2010 Sep 1;11(3):141-4. doi: 10.5152/jtgga.2010.21. eCollection 2010.</citation>
    <PMID>24591920</PMID>
  </reference>
  <reference>
    <citation>Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol. 2011 May;117(5):1114-21. doi: 10.1097/AOG.0b013e3182165ee8.</citation>
    <PMID>21508750</PMID>
  </reference>
  <reference>
    <citation>Taneepanichskul S, Reinprayoon D, Thaithumyanon P, Praisuwanna P, Tosukhowong P, Dieben T. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception. 2006 Apr;73(4):368-71. Epub 2005 Dec 27.</citation>
    <PMID>16531169</PMID>
  </reference>
  <reference>
    <citation>Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception. 2009 Dec;80(6):519-26. doi: 10.1016/j.contraception.2009.05.124. Epub 2009 Jul 10.</citation>
    <PMID>19913145</PMID>
  </reference>
  <reference>
    <citation>Braga GC, Ferriolli E, Quintana SM, Ferriani RA, Pfrimer K, Vieira CS. Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact. Contraception. 2015 Dec;92(6):536-42. doi: 10.1016/j.contraception.2015.07.009. Epub 2015 Jul 23.</citation>
    <PMID>26209863</PMID>
  </reference>
  <reference>
    <citation>Chapman DJ, Pérez-Escamilla R. Maternal perception of the onset of lactation is a valid, public health indicator of lactogenesis stage II. J Nutr. 2000 Dec;130(12):2972-80.</citation>
    <PMID>11110856</PMID>
  </reference>
  <reference>
    <citation>Sievers E, Haase S, Oldigs HD, Schaub J. The impact of peripartum factors on the onset and duration of lactation. Biol Neonate. 2003;83(4):246-52.</citation>
    <PMID>12743453</PMID>
  </reference>
  <reference>
    <citation>Dewey KG. Maternal and fetal stress are associated with impaired lactogenesis in humans. J Nutr. 2001 Nov;131(11):3012S-5S. Review.</citation>
    <PMID>11694638</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kate Ayers Shaw</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>contraceptive implant</keyword>
  <keyword>postpartum contraception</keyword>
  <keyword>breastfeeding and contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

